Compare EML & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | PMN |
|---|---|---|
| Founded | 1858 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.1M | 115.5M |
| IPO Year | 1995 | 2022 |
| Metric | EML | PMN |
|---|---|---|
| Price | $25.32 | $14.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | ★ 59.6K | 42.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 185.40 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $248,970,345.00 | N/A |
| Revenue This Year | $19.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $235.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $0.29 |
| 52 Week High | $29.91 | $27.40 |
| Indicator | EML | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 73.74 |
| Support Level | $18.34 | $10.55 |
| Resistance Level | $29.91 | $19.85 |
| Average True Range (ATR) | 1.39 | 0.90 |
| MACD | -0.06 | 0.34 |
| Stochastic Oscillator | 37.81 | 81.44 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.